TTrialPathMatch Me to Trials
← Back to trials
RecruitingParkinson Disease

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Eligible age

30–80 yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given. The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.

Sponsor: Appello Pharmaceuticals, Inc.

Where it's recruiting

Arkansas

Little Rock

California

Carlsbad · Los Alamitos · Los Angeles · Palo Alto

Colorado

Englewood

Florida

Boca Raton · Hallandale · Miami · Orlando …

Georgia

Augusta

Indiana

Indianapolis

Kansas

Kansas City

Kentucky

Lexington

Michigan

Ann Arbor · Farmington Hills

New Mexico

Albuquerque

New York

New York

Source: ClinicalTrials.gov · NCT07432958 · last updated 2026-10-28

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunc · TrialPath